Novavax: WHO nods malaria vaccine
(CercleFinance.com) - Novavax reports that the WHO has issued a recommendation for R21/Matrix-M, a vaccine to prevent malaria in children as young as 5 months of age.
WHO is drawing on advice from its Strategic Expert Group (SAGE) and Malaria Policy Group (MPAG).
The vaccine contains the R21 antigen developed by Oxford University, specific to the malaria parasite, and Novavax's Matrix-M, a saponin-based adjuvant that enhances the immune response, making it broader and more durable.
The dossier has been submitted to the WHO by Oxford, and the vaccine is being developed and manufactured by Serum Institute of India.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
WHO is drawing on advice from its Strategic Expert Group (SAGE) and Malaria Policy Group (MPAG).
The vaccine contains the R21 antigen developed by Oxford University, specific to the malaria parasite, and Novavax's Matrix-M, a saponin-based adjuvant that enhances the immune response, making it broader and more durable.
The dossier has been submitted to the WHO by Oxford, and the vaccine is being developed and manufactured by Serum Institute of India.
Copyright (c) 2023 CercleFinance.com. All rights reserved.